Robert Wasserman
Stock Analyst at Benchmark
(3.28)
# 1,055
Out of 5,090 analysts
111
Total ratings
47.66%
Success rate
2.5%
Average return
Main Sectors:
Stocks Rated by Robert Wasserman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRLB Proto Labs | Maintains: Buy | $45 → $55 | $52.08 | +5.61% | 7 | Nov 3, 2025 | |
| ITGR Integer Holdings | Downgrades: Hold | n/a | $69.84 | - | 12 | Oct 24, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Buy | $75 → $90 | $63.33 | +42.11% | 10 | Sep 24, 2025 | |
| INTS Intensity Therapeutics | Maintains: Speculative Buy | $4 → $1.5 | $0.51 | +194.12% | 7 | Aug 20, 2025 | |
| TECH Bio-Techne | Reiterates: Buy | $75 | $61.68 | +21.60% | 7 | Jun 5, 2025 | |
| KMDA Kamada | Reiterates: Buy | $15 | $7.08 | +111.86% | 2 | May 15, 2025 | |
| OABI OmniAb | Reiterates: Buy | $6 | $1.95 | +207.69% | 9 | May 12, 2025 | |
| XOMA XOMA Royalty | Initiates: Buy | $35 | $29.91 | +17.02% | 1 | Apr 17, 2025 | |
| ABCL AbCellera Biologics | Reiterates: Hold | n/a | $3.56 | - | 6 | Mar 3, 2025 | |
| BLFS BioLife Solutions | Reiterates: Buy | $30 | $25.46 | +17.83% | 6 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $8 | $2.26 | +253.98% | 6 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $5 | $5.65 | -11.50% | 3 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $12 | $11.90 | +0.84% | 17 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $1.83 | - | 7 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $164.98 | - | 3 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $3.42 | +16.96% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $0.28 | +1,338.85% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $75 | $2.83 | +2,550.18% | 2 | Apr 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $226.25 | - | 3 | Oct 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $580 | $572.77 | +1.26% | 1 | Jul 16, 2021 |
Proto Labs
Nov 3, 2025
Maintains: Buy
Price Target: $45 → $55
Current: $52.08
Upside: +5.61%
Integer Holdings
Oct 24, 2025
Downgrades: Hold
Price Target: n/a
Current: $69.84
Upside: -
Halozyme Therapeutics
Sep 24, 2025
Maintains: Buy
Price Target: $75 → $90
Current: $63.33
Upside: +42.11%
Intensity Therapeutics
Aug 20, 2025
Maintains: Speculative Buy
Price Target: $4 → $1.5
Current: $0.51
Upside: +194.12%
Bio-Techne
Jun 5, 2025
Reiterates: Buy
Price Target: $75
Current: $61.68
Upside: +21.60%
Kamada
May 15, 2025
Reiterates: Buy
Price Target: $15
Current: $7.08
Upside: +111.86%
OmniAb
May 12, 2025
Reiterates: Buy
Price Target: $6
Current: $1.95
Upside: +207.69%
XOMA Royalty
Apr 17, 2025
Initiates: Buy
Price Target: $35
Current: $29.91
Upside: +17.02%
AbCellera Biologics
Mar 3, 2025
Reiterates: Hold
Price Target: n/a
Current: $3.56
Upside: -
BioLife Solutions
Dec 19, 2024
Reiterates: Buy
Price Target: $30
Current: $25.46
Upside: +17.83%
Nov 19, 2024
Reiterates: Speculative Buy
Price Target: $8
Current: $2.26
Upside: +253.98%
Nov 12, 2024
Reiterates: Speculative Buy
Price Target: $5
Current: $5.65
Upside: -11.50%
Nov 7, 2024
Maintains: Buy
Price Target: $8 → $12
Current: $11.90
Upside: +0.84%
Nov 4, 2024
Reiterates: Hold
Price Target: n/a
Current: $1.83
Upside: -
Aug 5, 2024
Reiterates: Hold
Price Target: n/a
Current: $164.98
Upside: -
Mar 7, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $3.42
Upside: +16.96%
Mar 6, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $0.28
Upside: +1,338.85%
Apr 6, 2023
Reiterates: Speculative Buy
Price Target: $75
Current: $2.83
Upside: +2,550.18%
Oct 24, 2022
Downgrades: Hold
Price Target: n/a
Current: $226.25
Upside: -
Jul 16, 2021
Initiates: Buy
Price Target: $580
Current: $572.77
Upside: +1.26%